The Ebola virus causes an acute, serious illness which is often fatal if untreated. It first appeared in 1976 in 2 simultaneous outbreaks, one in what is now Nzara, South Sudan, and the other in Yambuku, DRC. The latter occurred in a village near the Ebola River, from which the disease takes its name.","datePublished":"2019-06-18T12:19:11.0000000+00:00","image":"https://cdn.who.int/media/images/default-source/ebola-drc/community-representatives-beni-ebola-congo-drc.tmb-0.jpg?sfvrsn=83f7502f_14","publisher":{"@type":"Organization","name":"World Health Organization: WHO","logo":{"@type":"ImageObject","url":"https://www.who.int/Images/SchemaOrg/schemaOrgLogo.jpg","width":250,"height":60}},"dateModified":"2019-06-18T12:19:11.0000000+00:00","mainEntityOfPage":"https://www.who.int/westernpacific/health-topics/ebola","@context":"http://schema.org","@type":"Article"};

World Bank Group/ V.Tremeau
Community representatives come to visit a family in the outskirts of Beni to raise awareness about Ebola.
© Credits

Ebola virus disease

    Overview

    Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness affecting humans and other primates.

    The virus is transmitted to people from wild animals (such as fruit bats, porcupines and non-human primates) and then spreads in the human population through direct contact with the blood, secretions, organs or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, clothing) contaminated with these fluids.

    The average EVD case fatality rate is around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks.

    The first EVD outbreaks occurred in remote villages in Central Africa, near tropical rainforests. The 2014–2016 outbreak in West Africa was the largest and most complex Ebola outbreak since the virus was first discovered in 1976. There were more cases and deaths in this outbreak than all others combined. It also spread between countries, starting in Guinea then moving across land borders to Sierra Leone and Liberia.

    It is thought that fruit bats of the Pteropodidae family are natural Ebola virus hosts.

    Symptoms

    The incubation period, that is, the time interval from infection with the virus to onset of symptoms, is from 2 to 21 days. A person infected with Ebola cannot spread the disease until they develop symptoms.

    Symptoms of EVD can be sudden and include: fever, fatigue, muscle, pain, headache, and sore throat. This is followed by vomiting, diarrhea, rash, symptoms of impaired kidney and liver function, and in some cases internal and external bleeding (e.g. oozing from the gums, blood in the stools). Laboratory findings include low white blood cell and platelet counts and elevated liver enzymes.

    It can be difficult to clinically distinguish EVD from other infectious diseases such as malaria, typhoid fever and meningitis. A range of diagnostic tests have been developed to confirm the presence of the virus.

    Treatment and prevention

     

    Supportive care - rehydration with oral or intravenous fluids - and treatment of specific symptoms improves survival. A range of potential treatments including blood products, immune therapies and drug therapies are currently being evaluated. 

    In the 2018-2020 Ebola outbreak in DRC, the first-ever multi-drug randomized control trial was conducted to evaluate the effectiveness and safety of drugs used in the treatment of Ebola patients under an ethical framework developed in consultation with experts in the field and the DRC.

    Two monoclonal antibodies (Inmazeb and Ebanga) were approved for the treatment of Zaire ebolavirus (Ebolavirus) infection in adults and children by the US Food and Drug Administration in late 2020.  

    The Ervebo vaccine has been shown to be effective in protecting people from the species Zaire ebolavirus, and is recommended by the Strategic Advisory Group of Experts on Immunization as part of a broader set of Ebola outbreak response tools. In December 2020, the vaccine was approved by the US Food and Drug Administration and prequalified by WHO for use in individuals 18 years of age and older (except for pregnant and breastfeeding women) for protection against Ebola virus disease caused by Zaïre Ebola virus. 

    In May 2020, the European Medicines Agency recommended granting marketing authorization for a 2-component vaccine called Zabdeno-and-Mvabea for individuals 1 year and older. 

    The vaccine is delivered in 2 doses: Zabdeno is administered first and Mvabea is given approximately 8 weeks later as a second dose. This prophylactic 2-dose regimen is therefore not suitable for an outbreak response where immediate protection is necessary.

     

     

     

    Publications

    All →
    Facilitation manual: psychological first aid during Ebola virus disease outbreaks, 2nd edition

    This manual is designed to orient helpers to offer psychological first aid (PFA) to people affected by an Ebola outbreak. PFA involves humane, supportive...

    Ebola and Marburg disease outbreaks: infection prevention and control research priorities in health care settings

    Ebola virus (EBOV) and Marburg virus (MARV) are associated with severe, potentially fatal, systemic diseases. During the development of the Infection Prevention...

    Extraordinary meeting of the 
Strategic Advisory Group of 
Experts on Immunization on Ebola 
vaccination, May 2024: conclusions 
and recommendations

    The Strategic Advisory Group of Experts (SAGE) on Immunization held an extraordinary meeting on 7 May 2024 on ebola vaccines. This report summarizes the...

    Infection prevention and control guideline for Ebola and Marburg disease, August 2023

    Ebola and Marburg disease outbreaks remain important public health threats. The newly published WHO Infection prevention and control guideline...

    Documents

    All →

    This protocol was written in accordance with the trial design and drug selection recommendations from the Filovirus therapeutics working group at WHO....

    During outbreaks of filovirus diseases (FVDs), health authorities should strengthen capacities for detection, reporting and management of cases and contacts,...

    This document provides a list of Filovirus vaccines and therapeutics licensed or under development for pathogens being considered as PRIORITY PATHOGENS.

    Solidarity Vaccine Trials_Core protocol cover page

    This adaptive multi-stage, multi-arm Solidarity Against (Filoviruses) Vaccine study protocol is designed as a living protocol that will be used to study...

    Our work

    Videos

    All →